MERRIMACK PHARMACEUTICALS IN's ticker is MACK and the CUSIP is 590328209. A total of 57 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 59.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $79,000 | +8.2% | 14,898 | 0.0% | 0.05% | +6.2% |
Q2 2018 | $73,000 | -39.2% | 14,898 | 0.0% | 0.05% | -41.5% |
Q1 2018 | $120,000 | -21.6% | 14,898 | 0.0% | 0.08% | -14.6% |
Q4 2017 | $153,000 | -29.5% | 14,898 | 0.0% | 0.10% | -32.9% |
Q3 2017 | $217,000 | – | 14,898 | – | 0.14% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Western Standard LLC | 1,063,267 | $4,253,000 | 4.83% |
22NW, LP | 1,241,896 | $4,968,000 | 2.52% |
Newtyn Management, LLC | 1,296,436 | $5,186,000 | 1.26% |
Bronte Capital Management Pty Ltd. | 531,510 | $2,052,000 | 0.36% |
WITTENBERG INVESTMENT MANAGEMENT, INC. | 186,198 | $620,000 | 0.33% |
Nantahala Capital Management | 751,943 | $3,008,000 | 0.09% |
Sepio Capital, LP | 194,785 | $779,000 | 0.08% |
Yakira Capital Management, Inc. | 66,934 | $268,000 | 0.08% |
LVW Advisors, LLC | 20,000 | $80,000 | 0.02% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 61,700 | $247,000 | 0.01% |